Clinical trial
An Open, Single-arm, Single-centre,Phase II Clinical Study Evaluating Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
NCT05856864 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open, Single-arm, Single-centre,Phase II Clinical Study Evaluating Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- June 1, 2024
- Completion date
- May 1, 2025
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced hepatocellular carcinoma that has failed at systemic therapy